BayMark Health Services Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- BayMark Health Services's estimated revenue is currently $38.9M per year.
- BayMark Health Services's estimated revenue per employee is $252468
- BayMark Health Services has 154 Employees.
- BayMark Health Services grew their employee count by 25% last year.
- BayMark Health Services currently has 29 job openings.
|David White||Chief Executive Officer at Baymark Health Services, Inc|
|Frank Baumann||Chief Operating Officer|
|Meleah Naylor||Treatment Center Director|
|Cindy Novak||Vice President of Human Resources|
|Vin Crispino||VP, Information Technology|
|Susan Meyercord||Vice President, General Counsel and Chief Compliance Officer|
|Gavin Scruggs||Senior Vice President, Development|
|Libby Rohlfing||Vice President, Payer Relations and Contracting|
|Wade Reed||Regional Vice President|
|Mike Saul||Division President|
What Is BayMark Health Services?
BayMark Health Services was formed in 2015 with the merger of two well-known and highly respected opioid treatment companies, BAART Programs and MedMark Treatment Centers. Together, these companies brought over 50 years of combined medication-assisted treatment (MAT) experience to create BayMark. Until 2016, BayMark had focused on providing MAT services in federally certified, state licensed, and CARF accredited Opiate Treatment Programs (OTP), using methadone and buprenorphine along with counseling and support services. In keeping with BayMark's mission to provide comprehensive medication-assisted treatment services, AppleGate Recovery and The Coleman Institute were acquired in 2017 and added to the BayMark family of treatment brands. AppleGate Recovery provides outpatient, medication-assisted treatment, through the use of buprenorphine products including, Suboxone®, Subutex®, Zubsolv® and Bunavail® with counseling and supportive recovery services. The physician's office setting provides patients more flexibility than a traditional, highly structured opioid treatment program. The Coleman Institute (TCI) has developed a unique and customizable approach to helping patients overcome their physical dependence on opioids. This treatment modality utilizes a medically-supervised, outpatient detoxification protocol, combined with naltrexone therapy, to help patients recover and remain abstinent from opiates. In late 2017, Health Care Resource Centers was acquired by Baymark. With 16 clinics across Maine, Massachusetts, and New Hampshire, patients can easily access medication-assisted treatment and counseling with the professional, supportive services that BayMark is known for. In March 2018, BayMark acquired Canadian Addiction Treatment Centres (CATC), the largest provider of opioid addiction treatment in Canada with 71 Opioid Treatment Programs (OTPs), 19 pharmacies and 1 residential treatment center in Ontario. BayMark will support CATC in their efforts to continue offering evidence-based treatment to those struggling with opiate addiction in Ontario, as well as expand to service those in need across Canada. Headquartered in Lewisville, Texas, BayMark Health Services also provides primary care and behavioral health services in select locations.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Medical Plus Su...||$12.7M||50||4%|
|IMO Managed Car...||$9.2M||36||3%|
|Hospice Brazos ...||$23.8M||94||3%|
BayMark Health Services News
AppleGate Recovery, a BayMark Health Services Company, announced the opening of its physician's office-based opioid treatment facility in ...
BayMark Health Services announced today the opening of MedMark Treatment Centers Lebanon, its second opioid treatment program (OTP) in ...
Olympic Peninsula Health Services reported it is able to accept new patients the same day they seek help and BayMark Health Services is ...
BayMark Health Services New Location/Offices
BayMark Health Services Acquisitions
|2017-01-26||The Coleman Institute||Article|
|2018-11-20||SpecialCare Hospital Management Corporation||Article|